Bio-Path Holdings shares are trading higher after the company announced interim results from its Phase 2 study of prexigebersen in combination with decitabine and venetoclax for the treatment of acute myeloid leukemia.
Portfolio Pulse from Benzinga Newsdesk
Bio-Path Holdings shares are trading higher following the announcement of positive interim results from its Phase 2 study of prexigebersen in combination with decitabine and venetoclax for treating acute myeloid leukemia.
June 14, 2024 | 11:54 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Bio-Path Holdings shares are trading higher after the company announced positive interim results from its Phase 2 study of prexigebersen in combination with decitabine and venetoclax for the treatment of acute myeloid leukemia.
The positive interim results from the Phase 2 study are a significant milestone for Bio-Path Holdings, indicating potential efficacy of their treatment for acute myeloid leukemia. This news is likely to boost investor confidence and drive the stock price higher in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100